Global Celiac Disease Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, By Drug Class (Vitamin & Mineral Supplements, Steroids & Immuno-suppressive Drugs, Enzyme-based Therapies, Tight-Junction Modulators, Tolerance-Inducing Immunotherapies, Others), By Disease Type (Classical CD, Non-Responsive CD, Refractory CD (Type I & II), Asymptomatic / Silent CD), By Line of Therapy (First Line, Second Line), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, By Company 2021-2031F 2021-2031F

Key Insights	Details
Forecast Period	2026 - 2031
Market Size (2025)	USD 673.39 Million
CAGR (2026-2031)	6.2%
Fastest Growing Segment	Enzyme-based therapies (7.48% CAGR to 2031)
Largest Market	North America
Market Size (2031)	USD 966.08 Million

Market Overview

The Global Celiac Disease Treatment Market is expected to grow from USD 673.39 Million in 2025 to USD 966.08 Million by 2031 at a 6.2% CAGR. Celiac disease treatment encompasses diagnostic methodologies, dietary management solutions, and emerging pharmacological interventions designed to mitigate symptoms, avert complications, and enhance patient well-being. The market's expansion is significantly driven by the increasing global prevalence of celiac disease, alongside heightened public and professional awareness that facilitates improved diagnosis rates. According to a systematic review and meta-analysis published in Gastroenterology in August 2026, approximately 1 in 120 individuals globally has biopsy-confirmed celiac disease. Furthermore, continuous advancements in diagnostic technologies and ongoing research into novel therapeutic approaches, including immune-modulators and enzymatic treatments, further support market growth.

Despite these growth factors, a significant impediment to market expansion remains the current absence of a definitive pharmacological cure for celiac disease, necessitating lifelong adherence to a strict gluten-free diet. This reliance on dietary management poses considerable challenges for patient compliance and quality of life, highlighting an unmet need for effective non-dietary treatments and limiting the full therapeutic market potential.

Key Market Drivers

Rising Prevalence and Growing Demand for Management
Approximately 1.5% of the global population exhibits positive serology compatible with celiac disease, indicating a substantial and growing patient pool requiring management and treatment solutions. This increasing prevalence, coupled with enhanced public health initiatives and improved diagnostic technologies, has led to a greater identification of affected individuals who seek medical interventions and dietary support. The expanded understanding of celiac disease's diverse clinical presentations also contributes to more accurate and earlier diagnoses, further stimulating demand within the market.

Therapeutic Advances and Investment Driving Market Expansion
The global Celiac Disease Treatment Market is also significantly propelled by continuous advancements in therapeutic interventions and the development of novel treatment options, moving beyond strict dietary adherence as the sole management strategy. For example, on October 8, 2026, argenx announced positive topline results from its Phase 2 study of FB102, an investigational CD122 inhibitor, in 126 adults with celiac disease, with plans to advance to Phase 3 development. This progress in pharmacological research underscores the industry's commitment to addressing the unmet medical needs of celiac patients. Such significant innovation attracts substantial investment, evidenced by argenx's agreement on July 27, 2026, to acquire Forte Biosciences for approximately $2.2 billion in equity value, partly driven by celiac disease research. These developments are crucial for offering alternatives or adjuncts to the gluten-free diet, thereby expanding the overall therapeutic landscape.

Download Free Sample Report

Key Market Challenges

Lack of pharmacological cure limits market growth
The absence of a definitive pharmacological cure for celiac disease fundamentally impedes the growth of the global celiac disease treatment market. This critical unmet need necessitates that patients adhere to a lifelong, strict gluten-free diet, which consistently presents significant challenges for patient compliance and overall quality of life. The enduring reliance on dietary management consequently limits the full therapeutic market potential for innovative non-dietary interventions.

Dietary non-adherence limits demand for pharmacologic therapies
For example, according to the National Celiac Association in March 2026, a global study revealed that one in three individuals with celiac disease were unable to consistently maintain a gluten-free diet. This substantial rate of non-adherence or accidental gluten exposure directly underscores the inherent limitations of dietary restrictions as the sole treatment modality. Such difficulties restrict the demand and development of pharmaceutical solutions that would otherwise offer more effective, comprehensive management of the underlying condition, thereby constraining the market for advanced celiac disease treatments.

Key Market Trends

Impact of Accelerated Regulatory Pathways on Celiac Therapy
Accelerated regulatory pathways represent a significant trend reshaping the global celiac disease treatment market by expediting the availability of novel therapies. These pathways, such as Fast Track designation, are crucial for drugs addressing serious conditions with unmet medical needs, potentially shortening development and review timelines. Such accelerated processes encourage pharmaceutical companies to invest further in celiac disease research, as the prospect of faster market entry increases return on investment. For example, Teva Pharmaceutical Industries' investigational anti-IL-15 antibody, TEV-53408, received U.S. Food and Drug Administration Fast Track designation in May 2025, highlighting its potential to address an urgent need for patients still symptomatic on a gluten-free diet. This regulatory support fosters innovation and offers hope for earlier access to new treatments that can move beyond strict dietary management.

Digital Health and Telehealth in Celiac Disease Management
The integration of digital health and telehealth platforms marks another impactful trend, enhancing patient management and accessibility to care within the celiac disease market. These platforms facilitate remote consultations, dietary counseling, and symptom monitoring, offering convenience and consistent support to patients navigating a lifelong gluten-free diet. This shift improves patient compliance and quality of life by providing personalized care solutions irrespective of geographical barriers. According to MyPreOp, August 9, 2025, in the 'Digital Health Adoption Statistics: 2026 Report', 71.4% of physicians in the United States were using telehealth weekly as of 2024, indicating a widespread acceptance of virtual care delivery. The increasing adoption of digital tools supports a more proactive and integrated approach to celiac disease management, broadening the scope of therapeutic interventions beyond traditional clinical settings.

Segmental Insights

Enzyme-based therapies as a leading growth driver in celiac disease treatment
The enzyme-based therapies segment represents a key growth driver within the Global Celiac Disease Treatment Market, emerging as the fastest-expanding category. This significant growth is primarily fueled by the urgent need for therapeutic options that either supplement or offer an alternative to the demanding lifelong strict gluten-free diet, which many patients struggle to adhere to consistently. Enzyme-based treatments effectively degrade immunogenic gluten peptides, providing a vital protective measure against inadvertent gluten exposure and mitigating persistent symptoms such as bloating and fatigue. Robust research and development initiatives by pharmaceutical companies, alongside increasing regulatory openness from entities like the U.S. FDA and European Medicines Agency, are further propelling innovation and market adoption in this promising therapeutic area.

Regional Insights

Diagnostics Leadership and Supportive Ecosystem Drive North America's Celiac Disease Treatment Market
North America leads the global celiac disease treatment market due to its advanced diagnostic capabilities, including widespread serological screening and improved healthcare provider awareness, which ensure earlier and more frequent disease detection. The region benefits from a robust ecosystem for drug development, characterized by numerous clinical trials and a favorable regulatory environment. Notably, the US Food and Drug Administration (FDA) provides guidance for novel celiac disease therapies. Furthermore, a well-established healthcare infrastructure with specialized gastroenterology clinics, coupled with strong patient advocacy and updated clinical guidelines from institutions like the American College of Gastroenterology, significantly drives market growth in the region.

Recent Developments

• In May 2025, Teva Pharmaceutical announced that its investigational drug, TEV-53408, received Fast Track designation from the U.S. Food and Drug Administration (FDA). This designation acknowledges TEV-53408's potential to address a critical unmet medical need for celiac disease patients who continue to experience symptoms despite adhering to a gluten-free diet. The therapy is being developed to act as a protective measure against accidental gluten exposure. The Fast Track status is expected to accelerate the development and regulatory review process for TEV-53408, highlighting its significance for the global celiac disease treatment market.
• In January 2025, Anokion SA reported positive symptom data from its Phase II ACeD-it trial evaluating KAN-101, a lead candidate for individuals with celiac disease. KAN-101 is an immunomodulatory agent specifically engineered to reprogram immune cells to tolerate gluten. The positive data from this mid-stage clinical trial indicate KAN-101's potential in suppressing the autoimmune response triggered by gluten exposure. This breakthrough research by Anokion SA contributes to the development of new pharmacological interventions, offering hope for patients seeking treatments beyond a strict gluten-free diet in the global celiac disease treatment market.
• In September 2024, Barinthus Biotherapeutics announced the initiation of its first-in-human Phase 1 clinical trial for VTP-1000, an investigational immunotherapy targeting celiac disease. This therapy utilizes the company’s proprietary SNAP Tolerance Platform, which aims to promote immune tolerance to gluten in affected individuals. The AVALON Study is designed to evaluate the safety and tolerability of VTP-1000 in adults diagnosed with celiac disease. The advancement of VTP-1000 into clinical trials represents a step in developing novel approaches beyond dietary restrictions for managing the autoimmune condition within the global celiac disease treatment market.
• In 2024, Novartis acquired Calypso Biotech, gaining full rights to CALY-002, a therapeutic monoclonal antibody for celiac disease treatment. This acquisition secured a significant asset designed to block interleukin-15 (IL-15), a primary contributor to inflammation in celiac disease and other autoimmune conditions. CALY-002 aims to alleviate gluten-induced intestinal damage and inflammation. Previously, the compound demonstrated a favorable safety and tolerability profile in a completed Phase 1a/b study involving healthy volunteers and individuals with well-controlled celiac disease, indicating its potential to advance therapeutic options within the global celiac disease treatment market.

Key Market Players

• Takeda Pharmaceuticals
• Innovate Biopharmaceuticals
• IMTherapeutics
• ImmunogenX
• First Wave BioPharma
• Anokion SA
• AMYRA Biotech AG
• Precigen Inc
• Allero Therapeutics
• Kanyos Bio

By Drug Class	By Disease Type	By Line of Therapy	By Route of Administration	By Distribution Channel	By Region
Vitamin & Mineral Supplements Steroids & Immuno-suppressive Drugs Enzyme-based Therapies Tight-Junction Modulators Tolerance-Inducing Immunotherapies Others	Classical CD Non-Responsive CD Refractory CD (Type I & II) Asymptomatic / Silent CD	First Line Second Line	Oral Parenteral Others	Hospital Pharmacy Retail Pharmacy Online Pharmacy	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Celiac Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Celiac Disease Treatment Market, By Drug Class:

• Vitamin & Mineral Supplements
• Steroids & Immuno-suppressive Drugs
• Enzyme-based Therapies
• Tight-Junction Modulators
• Tolerance-Inducing Immunotherapies
• Others

• Celiac Disease Treatment Market, By Disease Type:

• Classical CD
• Non-Responsive CD
• Refractory CD (Type I & II)
• Asymptomatic / Silent CD

• Celiac Disease Treatment Market, By Line of Therapy:

• First Line
• Second Line

• Celiac Disease Treatment Market, By Route of Administration:

• Oral
• Parenteral
• Others

• Celiac Disease Treatment Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

• Celiac Disease Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE